Skip to main content

Sengenics to Sell Sequenom's MaterniT21 Test in Malaysia, Singapore

NEW YORK (GenomeWeb News) – Sengenics today said that it has entered into an exclusive agreement with the Sequenom Center for Molecular Medicine to launch and promote Sequenom's MaterniT21 Plus prenatal testing service in Malaysia and Singapore.

Sengenics will offer the test, which detects Trisomy 13, 18, and 21, to its partner Ob/Gyn clinicians and hospitals in the two countries. Sengenics is based in Kuala Lumpur and offers genomic-based diagnostic services. It added that it has contracts with eight of the top 10 private hospital chains in the region.

Sequenom on Friday said that it has reached a 90,000 annualized test volume run rate for MaterniT21, approximately one year after the test was launched in the US.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.